1,2,3-三唑类α-淀粉酶和α-葡萄糖苷酶双酶抑制剂干预2型糖尿病的研究进展

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
K. Sruthi, S. L. Manju
{"title":"1,2,3-三唑类α-淀粉酶和α-葡萄糖苷酶双酶抑制剂干预2型糖尿病的研究进展","authors":"K. Sruthi,&nbsp;S. L. Manju","doi":"10.1002/ardp.70088","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>A series of fifteen 1,2,3-triazole derivatives <b>6(a–o)</b> were developed and evaluated for their inhibitory effects on carbohydrate-hydrolyzing enzymes implicated in Type 2 diabetes management. The compounds were assessed through in silico studies (including molecular docking and ADME predictions) and in vitro assays such as α-amylase, α-glucosidase, and antioxidant activities. Notably, the compounds <b>6a</b>, <b>6d</b>, <b>6g</b>, <b>6h</b>, <b>6k</b>, <b>6l</b>, and <b>6n</b> exhibited dual inhibition against both enzymes. Among them, compound <b>6a</b> exhibited the most potent α-glucosidase inhibition (IC<sub>50</sub> = 22.15 ± 0.75 µM), comparable to the reference drug acarbose (IC<sub>50</sub> = 21.07 ± 0.05 µM). Meanwhile, compound <b>6h</b> demonstrated strong α-amylase inhibition (IC<sub>50</sub> = 84.46 ± 1.14 µM) compared with standard acarbose (IC<sub>50</sub> = 87.62 ± 0.47 µM). Cytotoxicity studies of the most active compounds <b>6a</b> and <b>6h</b> indicated moderate cytotoxicity, with IC<sub>50</sub> values of 32.87 ± 1.2 µM and 32.42 ± 1.5 µM, respectively, suggesting a reasonable safety margin compatible with continued drug development. The DPPH assay revealed moderate to good activity for all compounds <b>6(a–o)</b>, with IC<sub>50</sub> values ranging from 39.60 ± 0.15 to 99.45 ± 0.12 µM. These findings support the therapeutic potential of these compounds as antidiabetic agents.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of 1,2,3-Triazoles as Dual Enzyme Inhibitors Targeting α-Amylase and α-Glucosidase for Type 2 Diabetes Intervention\",\"authors\":\"K. Sruthi,&nbsp;S. L. Manju\",\"doi\":\"10.1002/ardp.70088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>A series of fifteen 1,2,3-triazole derivatives <b>6(a–o)</b> were developed and evaluated for their inhibitory effects on carbohydrate-hydrolyzing enzymes implicated in Type 2 diabetes management. The compounds were assessed through in silico studies (including molecular docking and ADME predictions) and in vitro assays such as α-amylase, α-glucosidase, and antioxidant activities. Notably, the compounds <b>6a</b>, <b>6d</b>, <b>6g</b>, <b>6h</b>, <b>6k</b>, <b>6l</b>, and <b>6n</b> exhibited dual inhibition against both enzymes. Among them, compound <b>6a</b> exhibited the most potent α-glucosidase inhibition (IC<sub>50</sub> = 22.15 ± 0.75 µM), comparable to the reference drug acarbose (IC<sub>50</sub> = 21.07 ± 0.05 µM). Meanwhile, compound <b>6h</b> demonstrated strong α-amylase inhibition (IC<sub>50</sub> = 84.46 ± 1.14 µM) compared with standard acarbose (IC<sub>50</sub> = 87.62 ± 0.47 µM). Cytotoxicity studies of the most active compounds <b>6a</b> and <b>6h</b> indicated moderate cytotoxicity, with IC<sub>50</sub> values of 32.87 ± 1.2 µM and 32.42 ± 1.5 µM, respectively, suggesting a reasonable safety margin compatible with continued drug development. The DPPH assay revealed moderate to good activity for all compounds <b>6(a–o)</b>, with IC<sub>50</sub> values ranging from 39.60 ± 0.15 to 99.45 ± 0.12 µM. These findings support the therapeutic potential of these compounds as antidiabetic agents.</p></div>\",\"PeriodicalId\":128,\"journal\":{\"name\":\"Archiv der Pharmazie\",\"volume\":\"358 9\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archiv der Pharmazie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70088\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70088","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

开发了15个1,2,3-三唑衍生物6(A - o),并评估了它们对2型糖尿病治疗中涉及的糖水解酶的抑制作用。这些化合物通过计算机研究(包括分子对接和ADME预测)和体外实验(如α-淀粉酶、α-葡萄糖苷酶和抗氧化活性)进行评估。值得注意的是,化合物6a、6d、6g、6h、6k、6l和6n对这两种酶都有双重抑制作用。其中,化合物6a对α-葡萄糖苷酶的抑制作用最强(IC50 = 22.15±0.75µM),与对照药物阿卡波糖(IC50 = 21.07±0.05µM)相当。与标准阿卡波糖(IC50 = 87.62±0.47µM)相比,化合物6h具有较强的α-淀粉酶抑制作用(IC50 = 84.46±1.14µM)。细胞毒性研究显示,活性化合物6a和6h具有中等的细胞毒性,IC50值分别为32.87±1.2µM和32.42±1.5µM,表明具有合理的安全边际,可以继续进行药物开发。DPPH实验显示,化合物6(a-o)具有中等至良好的活性,IC50值为39.60±0.15 ~ 99.45±0.12µM。这些发现支持了这些化合物作为抗糖尿病药物的治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Development of 1,2,3-Triazoles as Dual Enzyme Inhibitors Targeting α-Amylase and α-Glucosidase for Type 2 Diabetes Intervention

Development of 1,2,3-Triazoles as Dual Enzyme Inhibitors Targeting α-Amylase and α-Glucosidase for Type 2 Diabetes Intervention

A series of fifteen 1,2,3-triazole derivatives 6(a–o) were developed and evaluated for their inhibitory effects on carbohydrate-hydrolyzing enzymes implicated in Type 2 diabetes management. The compounds were assessed through in silico studies (including molecular docking and ADME predictions) and in vitro assays such as α-amylase, α-glucosidase, and antioxidant activities. Notably, the compounds 6a, 6d, 6g, 6h, 6k, 6l, and 6n exhibited dual inhibition against both enzymes. Among them, compound 6a exhibited the most potent α-glucosidase inhibition (IC50 = 22.15 ± 0.75 µM), comparable to the reference drug acarbose (IC50 = 21.07 ± 0.05 µM). Meanwhile, compound 6h demonstrated strong α-amylase inhibition (IC50 = 84.46 ± 1.14 µM) compared with standard acarbose (IC50 = 87.62 ± 0.47 µM). Cytotoxicity studies of the most active compounds 6a and 6h indicated moderate cytotoxicity, with IC50 values of 32.87 ± 1.2 µM and 32.42 ± 1.5 µM, respectively, suggesting a reasonable safety margin compatible with continued drug development. The DPPH assay revealed moderate to good activity for all compounds 6(a–o), with IC50 values ranging from 39.60 ± 0.15 to 99.45 ± 0.12 µM. These findings support the therapeutic potential of these compounds as antidiabetic agents.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信